Personalize Medicine Consultant: Genomic Screening to Develop Sensitive Diagnostics and Effective Therapeutics

Technical Consultant #1553

Personalize medicine consultant which determines personal genetic risk markers with predisposition to disease.
Use of genomics, DNA sequencing and genotyping to identify the molecular bases of disease and characterizing subclassifications.
Expert in the use of genomic technology including microarray expression profiling, sequencing, and SNP analysis on the platforms developed by Illumina, Affymetrix, Helicos and Pacific Biosciences.
Embedded in the personalized medicine revolution including a founding role of a medical facility providing DNA testing revealing predisposition health conditions.
Expert in disease research within the areas of neurogenomics, neurological disease, cancer, drug development, diagnostic development and translational genomics.
Disease specific knowledge of autism, exercise-induced , Ph.D., M.D.heart attacks and sudden infant death syndrome (SIDDS), schizophrenia, bipolar disorders, Parkinson's, ALS (Lou Gehrig) and Alzheimer's disease.

Undisclosed Company, Founder and CSO, 2006 - Present

A diagnostics company which determines personal genetic risk markers which genetically predispose to disease.
Founded the company, developed the technical and product concepts and succeeded in procuring venture funding.

Undisclosed Company, Founder and Director, 2007 - 2009

A biopharmaceutical company focused on treatments for nervous system diseases including neurodegenerative diseases, impaired cognitive functions and mood disorders.
Founded the company based on discoveries within his research program at Translational Genomics Research Institute.
Successfully procure funding and began acquisition of drug use licenses.

Undisclosed Company, Founder and Director, 2008 - Present

A diagnostics company which evaluates individual cancer samples, determining unique genetic characteristics, and developing personalized treatment regimens.

Translational Genomics Research Institute (TGen), Phoenix, AZ, 2003 - 2008

Deputy Director for Discovery Research and Chairman Department of Neurogenomics

Oversaw 250 scientists with an overall funding portfolio of $70 million per year.
Structured the scientific goals and scope of the institute.
Raised funding for the institute including government and private grants, strategic partnerships and foundation funds.
Maintained a research lab focused on the discovery of genetic underpinnings of monogenic and complex genetic disorders including autism, exercise-induced heart attacks and sudden infant death syndrome, Schizophrenia, Bipolar, Parkinsons, ALS and Alzheimer's disease.
Headed the National Institutes of Health Neuroscience Microarray Consortium through the National Institute of Neurological Disorders and Stroke.

Academic and Professional Affiliations

Member, Society for Pediatric Research
Member, American Association of Cancer Research
Member, Society for Neuroscience
American Pediatric Society and Society for Pediatric Research Association Young Investigators Award
NIMH Advisory Panel for Complex Trait Genetics
Bio-IT Grand Prize "Discovery and Basic Research"
Mentor, Siemens-Westinghouse Science Fair Winners (Anne Lee and Albert Shieh)
Affymetrix "Center of Excellence for Genotyping and Resequencing"

Publications and Patents

Publications include over 120 articles in pier reviewed journals such as Science, the Proceedings of the National Academy of Sciences, Nature Genetics and the New England Journal of Medicine
Three published chapters in genomics and molecular medicine books
Twelve patents filed.